Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Or5.0
Ornithine – Forschung
Hilft vermutlich
32 begutachtete Studien
Was die Evidenz sagt
Hilft vermutlich
Ornithine half in etwa der Hälfte (3/5) der Studien, die einen Effekt gemessen haben — vielversprechend, aber nicht einhellig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1989–2026 mit einer typischen Studiengröße von 252 Teilnehmenden.
Basierend auf 32 Studien · 5 Meta-Analysen · 19 RCTs · 5,879 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
3geholfen2nicht geholfen· 27 weitere ohne bewertete Effektdaten
Nach Outcome
Hepatic encephalopathy
Hilft vermutlich13 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung6 Studien
Energy & fatigue
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
RecoverySchnellere Ammoniak-Clearance nach dem Training · Stunden nach dem Training
Sleep & insomniaKann die Schlafqualität verbessern · 1-2 Wochen · Die Ammoniak-Entgiftung reduziert Stresshormone und unterstützt so das Einschlafen · 1-2 Wochen
Zu wenige bewertete Studien1 Studie
Lean body mass & muscle growth
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 18 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
5,879
typische Studie: 252 Personen
Stärkste Designs
24
5 gepoolt, 19 randomisiert
Zeigte Nutzen
60%
3/5 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
1
3+ Monate
3
Untersuchte Populationen
Patients with cirrhosis and minimal hepatic encephalopathy2
Patients with overt hepatic encephalopathy2
Patients with cirrhosis and minimal HE1
Healthy subjects1
Aktives Forschungsgebiet
13 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
198920072026
1Reversal of minimal hepatic encephalopathyMeta-Analysen=292 · medium study2024
Einfach gesagt: LOLA has significant beneficial effects on reversal of MHE and prevention of OHE in patients with cirrhosis compared with placebo or no intervention.
He Q et al. · Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2024)
LOLA has significant beneficial effects on reversal of MHE and prevention of OHE in patients with cirrhosis compared with placebo or no intervention.
2Reversal of minimal hepatic encephalopathyMeta-Analysen=1,563 · large study2020
Einfach gesagt: In a meta-analysis of data from 25 trials, we found rifaximin and lactulose to be most effective for reversal of minimal HE in patients with cirrhosis.
Dhiman RK et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020)
In a meta-analysis of data from 25 trials, we found rifaximin and lactulose to be most effective for reversal of minimal HE in patients with cirrhosis.
L-ornithine L-aspartate and lactulose are most effective in the prevention of overt HE.
Lactulose was the only agent that was effective in reversing minimal HE, preventing overt HE, reducing ammonia, and improving quality of life, with tolerable adverse effects.
3Safety of L-ornithine oral intakeSystematische Übersicht2025
Einfach gesagt: The no observed adverse effect level was estimated to be 12,000 mg/person/day for L-Orn in the form of L-Orn hydrochloride.
Yang H et al. · Amino acids (2025)
The main observed adverse events were gastrointestinal disorders.
Indexing these adverse events, the no observed adverse effect level was estimated to be 12,000 mg/person/day for L-Orn in the form of L-Orn hydrochloride.
4Prevention of overt hepatic encephalopathyMeta-Analysen=384 · medium study2020
Einfach gesagt: These findings provide the first direct evidence of potential benefit of LOLA for the prevention of OHE in cirrhosis across a range of clinical presentations.
Butterworth RF · Metabolic brain disease (2020)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Treatment with LOLA resulted in significant reductions in the risk of progression to OHE in MHE patients (3 studies) with RR: 0.23 [95% CI: 0.07, 0.73], p < 0.01.
OHE prevention/prophylaxis was accompanied by significant reductions of blood ammonia.
Both oral and intravenous formulations of LOLA appeared to be effective for the prevention of progression to OHE in patients with MHE.
Einfach gesagt: L-ornithine-L-aspartate treatment may show a trend in superiority for clinical efficacy among standard interventions for OHE.
Zhu GQ et al. · Alimentary pharmacology & therapeutics (2015)
Spürbar Nutzen
← SchlechterKein EffektBesser →
In addition, L-ornithine-L-aspartate (MD -20.18, 95% CI -40.12 to -0.27) provided a significant reduction in blood ammonia concentration compared with observation.
L-ornithine-L-aspartate treatment may show a trend in superiority for clinical efficacy among standard interventions for OHE.
Rifaximin shows the greatest reduction in blood ammonia concentration, and treatment with neomycin demonstrates a higher probability in causing adverse effects among the five compared interventions.
6Reduction of abnormal neuropsychiatric testsSystematische Übersicht2019
Einfach gesagt: Lactulose, probiotics, and L-ornithine-L-aspartate are a low-cost alternative compared with antibiotic treatment.
Zucker DM et al. · Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates (2019)
Treatment of minimal hepatic encephalopathy with lactulose, probiotics, or L-ornithine-L-aspartate was seen to be equally effective in reducing abnormal tests at 1, 3, and 12 months post-treatment.
All patients with minimal hepatic encephalopathy should be screened using a neuropsychiatric test and receive treatment as needed.
Treatment can delay or eliminate risky automobile accidents and harm to self.
7MASLD treatment outcomesSystematische Übersichtn=1,671 · large study2026
Einfach gesagt: Preclinical evidence suggests that LOLA exerts pleiotropic hepatoprotective effects in MASLD by targeting hyperammonemia-induced fibrosis and metabolic dysregulation.
Ismaiel A et al. · European journal of clinical investigation (2026)
In clinical studies, results from three randomized controlled trials (RCTs) indicated significant improvements in liver enzymes (ALT, AST) and lipid profiles, with reductions in hepatic steatosis.
Evidence from six observational and open-label studies corroborated these biochemical improvements and further demonstrated significant reductions in blood ammonia levels, improved intrahepatic microcirculation and reduced liver stiffness and patient-reported fatigue.
Preclinical evidence suggests that LOLA exerts pleiotropic hepatoprotective effects in MASLD by targeting hyperammonemia-induced fibrosis and metabolic dysregulation.
8Improvement of hepatic encephalopathyMeta-Analysen=212 · medium study2009
Einfach gesagt: LOLA benefited patients with overt hepatic encephalopathy (I or II), whereas these data do not support the use of LOLA for patients with subclinical hepatic encephalopathy.
Jiang Q et al. · Journal of gastroenterology and hepatology (2009)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Likely real
LOLA versus placebo had a significant effect on improvement of hepatic encephalopathy (relative risk 1.89; 95% CI 1.32 to 2.71; P = 0.0005).
This comparison showed no statistical heterogeneity (P = 0.85 and chi(2) = 0.09).
LOLA benefited patients with overt hepatic encephalopathy (I or II), whereas these data do not support the use of LOLA for patients with subclinical hepatic encephalopathy.
9Improvement in grade of hepatic encephalopathyRCTn=140 · medium study2022
Einfach gesagt: Combination of LOLA with lactulose and rifaximin was more effective than only lactulose and rifaximin in improving grades of HE, recovery time from encephalopathy, with lower 28-day mortality.
Jain A et al. · Hepatology (Baltimore, Md.) (2022)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Higher rates of improvement in grade of HE (92.5% vs. 66%, p < 0.001), lower time to recovery (2.70 ± 0.46 vs. 3.00 ± 0.87 days, p = 0.03), and lower 28-day mortality (16.4% vs. 41.8%, p = 0.001) were seen in the LOLA group as compared with placebo.
Combination of LOLA with lactulose and rifaximin was more effective than only lactulose and rifaximin in improving grades of HE, recovery time from encephalopathy, with lower 28-day mortality.